-
BluTest Laboratories Expands UKAS Accreditation with EN 16777 for Advanced Virucidal Surface Testing
BluTest Laboratories – A Tentamus Company is pleased to announce a significant expansion to its UKAS accreditation scope with the addition of EN 16777, a critical virucidal Phase 2 Step 2 surface efficacy test designed for non-porous surfaces in medical settings. This marks the second scope extension for BluTest Laboratories in 2025, reflecting our continued commitment to staying at the forefront of regulatory virology testing. The EN 16777 standard plays a key role in demonstrating the efficacy of disinfectants against enveloped and non-enveloped viruses on surfaces commonly found in clinical and healthcare environments. It is a vital requirement for supporting product claims under the Biocidal Products Regulation (BPR). With this…
-
TentaConsult celebrates its fifth anniversary – A strong team, clear advice, reliable solutions!
Five years after its foundation, TentaConsult Pharma und Med GmbH can look back on an extremely positive year: the Münster-based company has established itself as a specialised consulting service provider for regulatory issues in the life sciences industry. With growing expertise and a growing team, TentaConsult supports manufacturers, regulatory affairs officers and quality managers in Germany, Europe and beyond. What began in summer 2020 with a clear focus on regulatory strategies, quality management and medical device and pharmaceutical law is now an established consultancy with around 30 employees, three locations and a steadily growing client base. In Martinsried near Munich, in Bordeaux and at its headquarters in Münster, TentaConsult supports…
-
TentaConsult feiert fünfjähriges Bestehen – Ein starkes Team, klare Beratung, verlässliche Lösungen!
Fünf Jahre nach der Gründung zieht die TentaConsult Pharma und Med GmbH eine überaus positive Bilanz: Das Unternehmen mit Sitz in Münster hat sich als spezialisierter Beratungsdienstleister für regulatorische Fragestellungen in der Life Sciences Branche etabliert. Mit wachsender Expertise und wachsendem Team unterstützt TentaConsult Hersteller, Zulassungsverantwortliche und Qualitätsmanagerinnen und -manager in Deutschland, Europa und darüber hinaus. Was im Sommer 2020 mit klarer Ausrichtung auf regulatorische Strategien, Qualitätsmanagement und Medizinprodukte- sowie Arzneimittelrecht begann, ist heute ein etabliertes Beratungsunternehmen mit rund 30 Mitarbeitenden, drei Standorten und einem stetig wachsenden Kundenstamm. In Martinsried bei München, in Bordeaux sowie am Hauptsitz in Münster begleitet TentaConsult Unternehmen entlang des gesamten Produktlebenszyklus – von der Idee…
-
Nova Biologicals Enhances Food Safety Portfolio with Major Expansion of Microbiological Testing Capabilities
Nova Biologicals, a Tentamus Group laboratory, today announced a significant expansion of its food safety testing services. The expansion adds critical testing for several key pathogens, providing food industry clients with more comprehensive, reliable results and faster confirmation times to ensure product safety and protect public health. Effective immediately, Nova Biologicals‘ accredited testing scope now includes: STEC (Shiga toxin-producing coli) Confirmatory Testingfor: Salmonella spp. Listeria spp. Listeria monocytogenes coli O157:H7 Clostridium perfringens Bacillus cereus(Petrifilm method) This enhancement addresses the growing industry demand for robust, all-in-one testing solutions. By bringing these advanced capabilities in-house, Nova Biologicals empowers its partners to identify potential contaminations with greater accuracy and efficiency, reinforcing supply chain…
-
Tentamus UK Announces Change in Country Management
The Tentamus Group announces a change in its country leadership. Effective July 1st, 2025, Nicola Berruti, Country Manager Tentamus Italy has been appointed as Country Manager for Tentamus Italy & UK. Nicola Berruti succeeds Dr. Frederick J. Stubbins, who will be pursuing new professional opportunities. “We are grateful for Fredericks commitment and efforts over the years and wish him all the best for his personal and professional journey ahead. Going forward, our Country Manager for Italy, Nicola Berruti, is appointed to Country Manager Italy & UK and will assume responsibility for our Italian and UK business”, said Dr. Christian Rebhan, CEO of the Tentamus Group. “With his extensive experience in…
-
CONIDIA CONIPHY launched a new service to track fungicide resistance
CONIDIA CONIPHY has added a new service to its portfolio to detect and monitor fungicide resistance of downy mildew disease in grapevine. After 5 years of research, development efforts and investment in new DNA/gene sequencing technologies, CONIDIA CONIPHY launched a new innovative method/tool: Fungi RESIST. Fungi RESIST can alert and measure resistance against fungicides used in the field. Downy mildew of grapevines is a devastating disease, and the use of fungicides is important to control and protect grapevines. An effective fungicide-resistance surveillance system is essential to detect fungicide resistance quickly before it spreads, helping preserve fungicide effectiveness and crop protection. In the context of global agricultural awareness of fungicide…
-
Tentamus North America Spotlights Expert Legionella Testing Services to Address Critical Public Health Risks
As the risk of Legionnaires‘ disease remains a critical public health concern, Tentamus North America is reinforcing its commitment to facility safety by highlighting its expert Legionella testing services for industries across the continent. The company is providing advanced, reliable testing solutions designed to help facility owners and managers proactively identify and mitigate Legionella contamination in building water systems. The critical importance of proactive Legionella testing is underscored by the bacteria’s prevalence in engineered water systems such as cooling towers, hot and cold water plumbing, spas, and fountains. Exposure to contaminated aerosols from these systems can lead to Legionnaires‘ disease, a severe form of pneumonia. Tentamus North America is uniquely positioned to support organizations in mitigating this…
-
Accelerating clinical development in Vienna
Turning breakthrough science into effective therapies requires more than innovation — it demands the right expertise, infrastructure, and seamless execution. This complexity is addressed by ClinXTrials – a powerhouse alliance based in Vienna. Gouya Insights, VelaLabs – a Tentamus company -, and ABF Pharmaceutical Services offer a one-stop solution to accelerate development and de-risk clinical translation. In the competitive world of biotechnology, companies face complex challenges in translating discoveries into successful clinical programs. With the right guidance, biotech companies can avoid unnecessary delays in preclinical development and move confidently toward clinical success. ClinXTrials unites deep expertise in clinical development, bioanalytic, and trial logistics to provide an integrated, end-to-end solution. Under…
-
Accelerator für klinischen Entwicklung in Wien
Bahnbrechende wissenschaftliche Erkenntnisse in wirksame Therapien zu überführen, erfordert mehr als nur Innovation – es bedarf der richtigen Expertise, Infrastruktur und reibungsloser Durchführung. Diese Komplexität wird bei ClinXTrials adressiert. Gouya Insights, VelaLabs – a Tentamus company – und ABF Pharmaceutical Services, drei innovative Unternehmen aus Wien, bieten gemeinsam eine integrierte Lösung an, um Entwicklungsprozesse zu beschleunigen und Risiken beim Übergang in die klinische Phase zu minimieren. In der wettbewerbsintensiven Biotechnologiebranche stehen Unternehmen vor der Herausforderung, wissenschaftliche Entdeckungen in erfolgreiche klinische Programme zu überführen. Mit der richtigen Unterstützung können Biotech-Firmen unnötige Verzögerungen in der präklinischen Phase vermeiden und bestärkt in Richtung klinischen Erfolg voranschreiten. ClinXTrials vereint umfassende Expertise in der klinischen…
-
The Oldenburg site of Tentamus Pharma & Med Deutschland GmbH celebrates its 30th anniversary this year
Since its founding in August 1995 as Dr. Kolkmann & Partner GmbH, the company has developed into an established player in the field of pharmaceutical analytics and drug research. Over the course of three decades, the site has undergone an impressive transformation. In 2008, the company was renamed Diapharm Analytics GmbH before being integrated into the internationally operating Tentamus Group in November 2018 – a significant step towards global networking and interdisciplinary collaboration. Since joining the Tentamus Group, the site has been operating under the name Tentamus Pharma & Med Deutschland GmbH and is now an integral part of the international network of over 90 laboratories and service facilities worldwide.…
